ReviewMicroorganisms2026
Microbial Natural Products Targeting the
Review in Microorganisms, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis (TB) remains one of the most significant global public health challenges, as it represents the world's leading infectious cause of death. The clinical efficacy of currently available anti-TB drugs is increasingly compromised due to the growing prevalence of antibiotic-resistant strains, side effects, and prolonged treatment times. This scenario highlights the urgent need to identify new anti-TB drugs with alternative mechanisms of action and improved anti-TB activity and bioavailability. In this context, natural products derived from microorganisms represent a key source of chemical diversity for drug discovery. Actinomycetes, fungi, and other environmental microbes produce a wide range of secondary metabolites with broad antimicrobial activity. These compounds can interfere with essential bacterial structures and processes, including membrane integrity, redox homeostasis, protein synthesis, and DNA replication. This review aims to evaluate new microbial natural products for their antibacterial activity, focusing on their efficacy, mechanisms of action, chemical nature, and potential clinical applications, with the aim of informing the development of new anti-TB agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.